



STATE BOARD OF OPTOMETRY
 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
 P (916) 575-7170 F (916) 575-7292 www.optometry .ca.gov



Continuing Education Course
 Approval Checklist

Title:

Provider Name:

Completed Application

Open to all Optometrists? Yes No

Maintain Record Agreement? Yes No

Correct Application Fee

Detailed Course Summary

Detailed Course Outline

PowerPoint and/or other Presentation Materials **Explanation letter attached**

Advertising (optional)

CV for EACH Course Instructor

License Verification for Each Course Instructor

Disciplinary History? Yes No

Cashiering and Board Use Only			
Receipt #	Payor ID	Beneficiary ID	Amount
1-2914	2799074	1136755	50

BUSINESS, CONSUMER SERVICES, AND HOUSING AGENCY

GVERNOR EDMUND G. BROWN JR.



STATE BOARD OF OPTOMETRY
 2450 DEL PASO ROAD, SUITE 105, SACRAMENTO, CA 95834
 P (916) 575-7170 F (916) 575-7292 www.optometry.ca.gov



CONTINUING EDUCATION COURSE APPROVAL APPLICATION

\$50 Mandatory Fee

Pursuant to California Code of Regulations (CCR) § 1536, the Board will approve continuing education (CE) courses after receiving the applicable fee, the requested information below and it has been determined that the course meets criteria specified in CCR § 1536(g).

In addition to the information requested below, please attach a copy of the course schedule, a detailed course outline and presentation materials (e.g., PowerPoint presentation). Applications must be submitted 45 days prior to the course presentation date.
 Please type or print clearly.

Course Title <u>Treatment for Macular Degeneration</u>	Course Presentation Date <div style="text-align: center; border: 1px solid black; padding: 5px;"> 0 5 / 0 7 / 2 0 1 7 </div>
--	--

Course Provider Contact Information

Provider Name		
<u>Keith</u> (First)	<u>Liang, MD</u> (Last)	_____ (Middle)

Provider Mailing Address			
Street <u>3160 J St.</u>	City <u>Sacramento</u>	State <u>CA</u>	Zip <u>95816</u>

Provider Email Address <u>spineda@liangvision.com</u>
--

Will the proposed course be open to all California licensed optometrists?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
Do you agree to maintain and furnish to the Board and/or attending licensee such records of course content and attendance as the Board requires, for a period of at least three years from the date of course presentation?	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO

Course Instructor Information

Please provide the information below and attach the curriculum vitae for each instructor or lecturer involved in the course. If there are more instructors in the course, please provide the requested information on a separate sheet of paper.

Instructor Name		
<u>Keith</u> (First)	<u>Liang</u> (Last)	_____ (Middle)
License Number <u>G 69355</u>	License Type <u>medical</u>	
Phone Number (916) <u>446-2020</u>	Email Address <u>spineda@liangvision.com</u>	

I declare under penalty of perjury under the laws of the State of California that all the information submitted on this form and on any accompanying attachments submitted is true and correct.

1.31.2017
Signature of Course Provider
Date

Course Title	Date(s) of Course	Instructor(s)/Lecturer(s)	CE Hours Requested	FOR BOARD USE ONLY		
				Approved	Disapproved	ID #
Toric IOL's	01/18/2017	KEITH LIANG, MD	2			
Corneal Cross-Linking	03/15/2017	KEITH LIANG, MD	2			
Review of Eye Drops: Prostaglandins	05/17/2017	KEITH LIANG, MD	2			
Aspheric vs. Non-Aspheric: Night Time Vision	07/19/2017	KEITH LIANG, MD	2			
Tecnis, Symphony & Crystalens AO	09/13/2017	KEITH LIANG, MD	2			
Wavefront Technology: Topography Guided Laser	11/15/2017	KEITH LIANG, MD	2			
Treatments for Macular Degeneration	05/07/2017	KEITH LIANG, MD	2			
Glaucoma: Decisions & Choices	05/07/2017	KEITH LIANG, MD	2			
Ocular Hypertension	11/12/2017	KEITH LIANG, MD	2			
Optical Coherence Tomography of Macula & Optic	11/12/2017	KEITH LIANG, MD	2			
COMMITTEE COMMENTS:						

February 23, 2017

**State Board of Optometry
2450 Del Paso Road, Suite 105
Sacramento, CA 95834**


Dear Boards of Optometry,

Thank you for considering my request for CE approval. I was recently informed by Kristina Eklund that I need to provide a letter to explain why I am not able to provide presentation materials for the scheduled events in 2017. I feel that providing current information to our network of optometrist is very important. I gather presentation information from a variety of information sources- mainly current ophthalmic studies (articles) and ophthalmic meetings that I attend periodically through the year. The Power Point presentations are created from information gathered from ASCRS held in May and AAO conferences held in November; this ensures that the information provided is not only current, but the newest technology that we can offer in the United States.

I have prided myself in the ability to deliver quality information to my optometric network and I have been working with the Board of Optometry for many years to provide CE's. I ask that you strongly consider issuing Continuing Education credits for 2017 as I have many Optometrists who depend on what is offered at my office.

Thank you so much for your consideration.

Sincerely,



Keith Liang, MD
Ophthalmologist



(916) 446-2020 • Fax: (916) 446-3128
3160 J Street • Sacramento • CA • 95816-4403

COURSE SUBJECT MATTER

Event Date: May 7, 2017

Treatments for Macular Degeneration

Instructor: Keith Liang, MD

Review the clinical indications to treat with IVI Avastin. What are the criteria to treat classic SRNV vs. non-classic SRNV? Data review of clinical outcomes with multiple injections and long term follow will be reviewed. Current treatment modalities of PDT, IVI and Focal Argon or Krypton lasers will be discussed. The goals are to provide the optometrist with the latest evidenced based treatment for Macular Degeneration.

Glaucoma : Decisions and Choices

Instructor: Keith Liang, MD

Decision making process of primary drop selection assessment of treatment. What is adequate treatment versus not adequate treatments. What are possible alternative second line drugs or laser treatments.

Event Date: November 12, 2017

Ocular Hypertension

Instructor: Keith Liang, MD

The OHTN and AGS studies will be reviewed to help clarify when the best time to treat ocular hypertensive patients is. This difficult area of treatment has created numerous medical and ethical discussions. The goal will be to clarify the topic on order for optometrist to gain insight into this area.

Optical Coherence Tomography of the macula and optic nerve

Instructor: Keith Liang, MD

This technology aids in the diagnosis and treatment of retinal macular edema. It can assess the progress of treatments such as intravitreal injections and laser therapy. This tool can also assess the progress of the optic nerve and glaucoma. It has changed the practice of retinal and glaucoma management. The principle of how to read a basic scan will be reviewed.

OUTLINE

Treatments for Macular Degeneration: Keith Liang, MD

1. Macular degeneration is a deterioration or breakdown of the macula. The macula is a small area in the retina at the back of the eye that allows you to see fine details clearly and perform activities such as reading and driving. Macular degeneration is the leading cause of severe vision loss in Caucasians over 65.
 - a. Macular degeneration is a deterioration or breakdown of the macula. The macula is a small area in the retina at the back of the eye that allows you to see fine details clearly and perform activities such as reading and driving.
 - i. Approximately 90% of patients have the Dry form which progresses slowly. Vitamins may slow the progression in 20-25% of patients.
 - ii. The Wet form occurs in approximately 10% of patients and can cause bleeding and sudden loss of vision.
 - b. Macular degeneration can cause different symptoms in different people. The condition may be hardly noticeable in its early stages. Sometimes only one eye loses vision while the other eye continues to see well for many years.
 - i. Some common ways vision loss is detected
 1. words on a page look blurred
 2. a dark or empty area appears in the center of vision
 3. Straight lines look distorted.

KEITH LIANG M.D.

CORNEAL, CATARACT, GLAUCOMA AND REFRACTIVE SURGEON

*3160 J STREET
SACRAMENTO, CA 95816-4403
(916) 446-2020
kliang@liangvision.com*

PRIVATE PRACTICE

**CENTER FOR SIGHT CLINIC AND
LASER CENTER 1995 – Present**

SACRAMENTO EYE SURGICENTER

Medical Director 1999 – Present
3150 J Street
Sacramento, CA 95816

EDUCATION

CHIEF RESIDENCY

*LSU – Lions Eye Center 1993 – 1994
Cornea and Refractive Surgery
New Orleans, Louisiana*

RESIDENCY

*Louisiana State Univ. Medical Center
1990 – 1994
New Orleans, Louisiana*

INTENRSHIP

*University of Southern California-
Los Angeles County Medical Center
1989 – 1990
Los Angeles, California*

MEDICAL SCHOOL

*University of Southern California-
Keck School of Medicine
1985 – 1989
Los Angeles, California*

UNDERGRADUATE

*University of California at Los Angeles
1982 – 1985
Los Angeles, California*

MEMBERSHIPS

American Academy of Ophthalmology
American Board of Ophthalmology
American Society of Cataract and Refractive Surgery
International Society of Refractive Surgery
New Orleans Academy of Ophthalmology
Association for Research in Vision and Ophthalmology

PAPERS

“Introduction to the 13th NIDEK International Refractive Symposium: Cyberspace”
Journal of Refractive Surgery, Volume 25, January (Suppl) 2009

“Vision Quest” – By Reed Parsell/photography by 521Productions.com
Sacramento Magazine, 174, 176–177, September 2007

“New NSAID Speeds Resolution of Corneal Ulcer”
Ophthalmology Management 49–50, January 2006

“Acrysof Restor IOL Presbyopic lens removal and exchange”
Cataract & Refractive Surgery Today Volume 6, No. 4: 66–69, April 2006

“Wavefront–Adjusted Treatments on the Nidek EC–5000”
Cataract & Refractive Surgery Today 82–84, August 2004

“Cohesive viscoelastic offers predictable protection – Surgeon depends on high-viscosity agent for 95% of cataract cases” – By Lynda Charters, Reviewed by Keith Liang, M.D.
Ophthalmology Times 34, February 15, 2003

“A Comparison of the Nidek EC-5000, Visx S2 and Summit Apex Lasers”
Review of Ophthalmology Part 3 of 3: 6–7, July 2001

“Fungal Keratitis from Nylon Lawn Trimmers”
American Journal of Ophthalmology 114:437–440, October 1992

“Browns Superior Oblique Tendon syndrome After Baerveldt Implant”
Archives of Ophthalmology 110:1368, 1992

CLINICAL TRIALS

CRS – NIDEK Clinical treatment of Astigmatism IDE 1999 – 2000
CLARITY Holos-On going study to develop intraoperative aberrometry for Cataract Surgery.

ACOES Cross linking investigation- evaluate efficacy of cornea collagen crosslinking in Keratoconus and Ectasia eyes

CRS/ISRS – LASIK Clinical investigation: Evaluate the efficacy of LASIK and submit data to FDA Device Committee 1996 – 1998

CRS/ISRS – VISX Clinical treatment of Astigmatism and high myopia IDE 1996 – 1997

NIDEK PRK Study Site – worked under supervision of Marguerite McDonald M.D. in New Orleans, LA – 1994

AUTONOMOUS – Preliminary monkey treatments at Tulane vivarium under the direction of Marguerite McDonald M.D. – 1994

PRESENTATIONS

AAO Intraoperative Aberrometry –HOLOS for refractive cataract surgery. IOL Predictor 2016

ASCRS Intraoperative Aberrometry –HOLOS for refractive cataract surgery 2015

ASCRS- Topography guided laser- How to use the CATZ and OATZ software to achieve optimal results- NIDEK 2014

AAO – Laser assisted Cataract Surgery- Femto LRI incisions with Lensar laser 2013

OPTOMETRIC – Semi-annual half-day lectures to local Optometrists regarding various topics in Ophthalmology – 1995 – 2009 – Sacramento, CA

OPTOMETRIC – Bi-monthly dinner lectures to local Optometrists regarding various topics in Ophthalmology – 1995 – 2009 – Sacramento, CA

CRS – How to remove a multifocal lens – December, 2007 – Las Vegas, NV

ASCRS – Akahoshi technique with the millennium system. Bausch & Lomb – 2005 Washington, D.C.

ASCRS – Nidek wavefront adjusted myopic treatments utilizing 6.5/7.5 zones compared to non-wavefront treatments – 2004 San Diego, CA

ASCRS – Combination Akahoshi pre-chop and flip technique for cataract surgery – 2001

ASCRS – LASIK Video Grand Rounds: Complications and Management-panel member – 1999 – 2001

AAO – LASIK Video Grand Rounds: Complications and Management-panel member – 1999 – 2001

ASCRS – Comparison of NIDEK, VISX and Summit Lasers for the LASIK treatment of myopic astigmatism – 2000

ASCRS – Initial clinical pearls for the insertion of Starr Posterior ICL – a beginning surgeon’s experience – 2000

ASCRS – Results of Mobile VISX Laser in the LASIK treatment of myopic astigmatism – 1999

FDA DEVICE PANEL – Gaithersburg, Maryland - presented LASIK data for FDA approval of LASIK procedure – 1998

LSU- New Orleans Academy- Pigmentary Dispersion Glaucoma- Laser Peripheral Iridectomy- clinical trial of P.I. in myopic patients with posterior bowing of iris plane 1992

ARVO- Fluorescein angiographic Histopathological Correlation of Dihematoporphyrin/Argon Laser Treated Vasculature & Subretina Neovascularization 1988

CERTIFICATION

2016- ALLEGRETTO WAVE EYE-Q 400HZ

2015 – HOLOS ABERROMETRY FOR CATARACT SURGERY

2014- ZIEMER S FEMTO LDV CRYSTALLINE-BLADE FREE

2013 – Glaucoma- ISTENT IMPLANT

2012 – LENSAR FEMTOSECOND LASER

2008 – Glaucoma – TRABECUTOME SURGERY

2007 – STAAR INTRAOCULAR CONTACT LENS

2007 – MULTIFOCAL REZOOM LENS

2007 – ASTIGMATISM LENS TORIC

2006 – MULTIFOCAL RESTORE LENS

2006 – VERISYSE INTRAOCULAR CONTACT LENS

2005 – Glaucoma – SELECTIVE LASER TRABECULOPLASY

2004 – ALLEGRETTO EXCIMER LASER SYSTEM

2004 – CRYSTALENS

2000 – LADAR VISION EXCIMER LASER SYSTEM
1999 – NIDEK EXCIMER LASER SYSTEM
1996 – VISX EXCIMER LASER SYSTEM
1995 – SUMMIT EXCIMER LASER SYSTEM

OUTLINE

Treatments for Macular Degeneration: Keith Liang, MD

1. Macular degeneration is a deterioration or breakdown of the macula. The macula is a small area in the retina at the back of the eye that allows you to see fine details clearly and perform activities such as reading and driving. Macular degeneration is the leading cause of severe vision loss in Caucasians over 65.
 - a. Macular degeneration is a deterioration or breakdown of the macula. The macula is a small area in the retina at the back of the eye that allows you to see fine details clearly and perform activities such as reading and driving.
 - i. Approximately 90% of patients have the Dry form which progresses slowly. Vitamins may slow the progression in 20-25% of patients.
 - ii. The Wet form occurs in approximately 10% of patients and can cause bleeding and sudden loss of vision.
 - b. Macular degeneration can cause different symptoms in different people. The condition may be hardly noticeable in its early stages. Sometimes only one eye loses vision while the other eye continues to see well for many years.
 - i. Some common ways vision loss is detected
 1. words on a page look blurred
 2. a dark or empty area appears in the center of vision
 3. Straight lines look distorted.